Skip to main content

Table 3 Clinical and parasitological response by treatment group for subjects completing follow up

From: Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial

Response

n(%)

SP

N = 174

AS/SP

N = 182

Total

N = 356

P*

Re-infection

18 (10.3)

9 (4.9)

27 (7.6)

0.054

Success (ACPR)

138 (88.5)

169 (97.7)

307 (93.3)

0.0008

Treatment failure

18 (11.5)

4 (2.3)

22 (6.7)

0.0008

   ETF

5 (3.2)

3 (1.7)

8 (2.4)

0.39

   LCF

4 (2.6)

0

4 (1.2)

0.03

   LPF

9 (5.8)

1 (0.6)

10 (3.0)

0.006

  1. As patients with re-infection were withdrawn and rescued prior to study completion they are excluded form denominators for ACPR and treatment failure
  2. SP: sulphadoxine-pyrimethamine
  3. AS/SP: artesunate/sulphadoxine-pyrimethamine
  4. ACPR: adequate clinical and parasitological response
  5. ETF: early treatment failure
  6. LCF: late clinical failure
  7. LPF: late parasitological failure
  8. *2-sample test of proportions